1. Home
  2. KRYS vs LNTH Comparison

KRYS vs LNTH Comparison

Compare KRYS & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • LNTH
  • Stock Information
  • Founded
  • KRYS 2015
  • LNTH 1956
  • Country
  • KRYS United States
  • LNTH United States
  • Employees
  • KRYS N/A
  • LNTH N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • KRYS Health Care
  • LNTH Health Care
  • Exchange
  • KRYS Nasdaq
  • LNTH Nasdaq
  • Market Cap
  • KRYS 4.3B
  • LNTH 3.6B
  • IPO Year
  • KRYS 2017
  • LNTH 2015
  • Fundamental
  • Price
  • KRYS $150.49
  • LNTH $58.21
  • Analyst Decision
  • KRYS Strong Buy
  • LNTH Strong Buy
  • Analyst Count
  • KRYS 10
  • LNTH 6
  • Target Price
  • KRYS $204.90
  • LNTH $105.50
  • AVG Volume (30 Days)
  • KRYS 422.6K
  • LNTH 2.5M
  • Earning Date
  • KRYS 08-04-2025
  • LNTH 08-06-2025
  • Dividend Yield
  • KRYS N/A
  • LNTH N/A
  • EPS Growth
  • KRYS 36.22
  • LNTH N/A
  • EPS
  • KRYS 4.91
  • LNTH 3.77
  • Revenue
  • KRYS $359,205,000.00
  • LNTH $1,520,653,000.00
  • Revenue This Year
  • KRYS $34.33
  • LNTH $4.57
  • Revenue Next Year
  • KRYS $47.84
  • LNTH $9.41
  • P/E Ratio
  • KRYS $30.77
  • LNTH $15.42
  • Revenue Growth
  • KRYS 116.08
  • LNTH 5.75
  • 52 Week Low
  • KRYS $122.80
  • LNTH $47.25
  • 52 Week High
  • KRYS $207.84
  • LNTH $118.21
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 56.41
  • LNTH 40.12
  • Support Level
  • KRYS $142.51
  • LNTH $55.00
  • Resistance Level
  • KRYS $147.58
  • LNTH $56.16
  • Average True Range (ATR)
  • KRYS 4.78
  • LNTH 2.52
  • MACD
  • KRYS 0.39
  • LNTH 0.57
  • Stochastic Oscillator
  • KRYS 92.81
  • LNTH 41.41

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Share on Social Networks: